Cargando…

Sex — a potential factor affecting immune checkpoint inhibitor therapy for cancers

Detalles Bibliográficos
Autores principales:	Hu, Wang, Qian, Xinye, Wang, Shuang, Gao, Lu, Xu, Jingyi, Yan, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622749/ https://www.ncbi.nlm.nih.gov/pubmed/36330508 http://dx.doi.org/10.3389/fimmu.2022.1024112

Ejemplares similares

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
por: Qian, Xinye, et al.
Publicado: (2022)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
por: González-Navajas, Jose M., et al.
Publicado: (2021)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors
por: Yang, Ximing, et al.
Publicado: (2022)

Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors
por: Chong, Pei Pei, et al.
Publicado: (2022)

PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
por: Gao, Yuan, et al.
Publicado: (2022)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
por: Wang, Xueyan, et al.
Publicado: (2022)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
por: Li, Haohao, et al.
Publicado: (2022)

Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy
por: Zhou, Jiebai, et al.
Publicado: (2023)

Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies
por: Zhou, Binghan, et al.
Publicado: (2021)

Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers
por: Wang, Jingting, et al.
Publicado: (2022)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy
por: Chen, Xingyu, et al.
Publicado: (2021)

Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer
por: Chen, Chen, et al.
Publicado: (2021)

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma
por: Wang, Qi, et al.
Publicado: (2023)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy
por: Plesca, Ioana, et al.
Publicado: (2020)

Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma
por: Sharma, Rohini, et al.
Publicado: (2021)

Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review
por: Lin, Chen, et al.
Publicado: (2023)

Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report
por: Cheng, Yuan, et al.
Publicado: (2022)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Qiu, Hui, et al.
Publicado: (2021)

Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma
por: Jia, Jianlong, et al.
Publicado: (2022)

Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma
por: Li, Xin, et al.
Publicado: (2021)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
por: Ghouzlani, Amina, et al.
Publicado: (2021)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Cutaneous manifestations associated with immune checkpoint inhibitors
por: Watanabe, Tomoya, et al.
Publicado: (2023)

Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes
por: Qi, Yangzhi, et al.
Publicado: (2020)

Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors
por: Liu, Wenhui, et al.
Publicado: (2021)

The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer
por: Zeng, Hao, et al.
Publicado: (2022)

Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition
por: Zheng, Guoxing, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
por: Tang, Liansha, et al.
Publicado: (2021)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_28i03196j9coa6jme1r6elq690